I find it revealing to read stock investor blogs for the insight they give about how investors view the various therapeutic candidates for CML. The following article is a good example of what I mean and is interesting for what it says generally about TKI therapies - and how things might change when imatinib goes off patent in 2015 (US) and 2016 (EU).
BTW: I do not invest in the stock market-!
Sandy
Why Ariad's Iclusig Is A Potential Blockbuster
Jun 3 2013, 16:24 | 5 comments
http://seekingalpha.com/article/1477891-why-ariad-s-iclusig-is-a-potenti...